ASCO 2018
ASCO 2018 Prostate Cancer
- ASCO 2018: Pembrolizumab plus Enzalutamide in mCRPC: Extended Follow Up
- ASCO 2018: Enzalutamide Plus CC-115 in Men with mCRPC: A Phase 1b Prostate Cancer Clinical Trials Consortium Study
- ASCO 2018: Perspective on Balancing Toxicities in the Treatment of mHSPC
- ASCO 2018: Long-Term Androgen Deprivation, With or Without Radiotherapy, in Locally-Advanced Prostate Cancer: Updated Results from a Phase III Randomized Trial
- ASCO 2018: Optimal Patient Selection/Stratification Perspective
ASCO 2018 Bladder Cancer
- ASCO 2018: Optimization of PD-L1 Algorithm for Predicting OS in Patients with Urothelial Cancer Treated with Durvalumab
- ASCO 2018: Tailoring of Chemotherapy to Fit Patients with Metastatic Urothelial Cancer
- ASCO 2018: Targeted Therapies in Advanced Urothelial Cancer
- ASCO 2018: Immunotherapy-Based Approaches for Advanced Urothelial Cancer
- ASCO 2018: Relapse-Free Survival of Clinical T2-4N0 Urothelial Bladder Carcinoma After Radical Cystectomy, with or without Perioperative Chemotherapy: Endpoints for Clinical Trial Design.
ASCO 2018 Renal Cancer
- ASCO 2018: Measurable Immunologic Changes and Improved Clinical Activity in mRCC with Nivolumab + Bevacizumab or Nivolumab + Ipilimumab
- ASCO 2018: CABOPRE: Phase II Study of Cabozantinib Prior to Cytoreductive Nephrectomy in Locally Advanced and/or Metastatic Renal Cell Carcinoma
- ASCO 2018: KEYNOTE-564: A Phase 3, Randomized, Double Blind, Trial of Pembrolizumab in the Adjuvant Treatment of Renal Cell Carcinoma
- ASCO 2018: Nivolumab for Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Institution Experience
- ASCO 2018: Effectiveness and Safety of Pazopanib and Everolimus in a Changing Treatment Landscape: Interim Results of the Non-Interventional Study PAZOREAL
ASCO 2018 Penile Cancer
ASCO 2018 Testicular Cancer
- ASCO 2018: Approaches in Management of Refractory Germ Cell Cancer
- ASCO 2018: Survivorship and Surveillance in Management of Germ Cell Cancer
- ASCO 2018: State-of-the-Art Management of Germ Cell Cancer
- ASCO 2018: Multicenter Randomized Phase 2 Trial of Paclitaxel, Ifosfamide, and Cisplatin Versus Bleomycin, Etoposide, and Cisplatin for First-line Treatment of Patients with Intermediate- or Poor-risk Germ Cell Tumors
- ASCO 2018: Circulating miR-371a-3p for the Detection of Low Volume Viable Germ Cell Tumor: Expanded Pilot Data, Clinical Implications and Future Study
ASCO 2018 Press Releases
- ASCO 2018: Updated Phase 1 Data Announced for Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
- ASCO 2018: Phase III Trial Finds Many People with Advanced Kidney Cancer Do Not Need Surgery
- ASCO 2018: Geriatric Assessment Improves Communication Between Oncologists and Older Patients
- ASCO 2018: Abiraterone May Be More Effective in Black Men with Advanced Prostate Cancer than in White Men
- ASCO 2018: Black Men with Advanced Prostate Cancer Treated with Chemotherapy May Have Equal or Better Survival than White Men